IgA nephropathy (Berger disease) — mesangial IgA glomerulonephritis
Bedside summary
Commonest primary glomerulonephritis worldwide (high prevalence in East Asia; common in South Asia). Mesangial deposition of galactose-deficient IgA1 immune complexes. Classic presentations: synpharyngitic visible (macroscopic) haematuria within 1-2 days of a mucosal infection (vs ~2 weeks in post-strep GN), or incidental microscopic haematuria + proteinuria. Course ranges from benign to progressive CKD; a minority present with RPGN/crescentic disease or AKI. Management centres on maximal supportive kidney-protective therapy, with immunosuppression reserved for high-risk/progressive disease.
Red flags
- Rapidly rising creatinine with RBC casts — crescentic/RPGN transformation, urgent biopsy + immunosuppression
- AKI following an episode of visible haematuria (ATN from tubular haem pigment, or crescents)
- Malignant hypertension
- Nephrotic-range proteinuria (may indicate coexisting minimal-change lesion or advanced disease)
- Older patient with new visible haematuria — exclude urological malignancy before attributing to IgAN
Assessment
Differential diagnosis
- Post-infectious (post-streptococcal) GN — latent period ~1-3 weeks, low C3, raised ASOT
- IgA vasculitis (Henoch-Schonlein) — same deposits plus purpura/arthritis/GI involvement
- Thin basement membrane disease / Alport (familial haematuria)
- Other causes of glomerular haematuria (lupus, MPGN, anti-GBM)
- Urological causes of visible haematuria (stones, tumour, UTI) — exclude in older patients
Investigations
- Urine microscopy (dysmorphic RBCs, red cell casts), urine PCR/ACR to quantify proteinuria
- U&E/creatinine/eGFR trend; BP
- Complement C3/C4 (typically normal in IgA, low in post-strep/MPGN/lupus), ASOT/anti-DNase B, ANA, ANCA/anti-GBM if rapid decline
- HBV/HCV/HIV; serum IgA (raised in a minority, not diagnostic)
- Renal ultrasound; renal biopsy for diagnosis + MEST-C Oxford score (prognostic) when proteinuria/impairment or diagnostic uncertainty
- If AKI/RPGN picture: urgent biopsy to identify crescents
Management
- Confirm diagnosis on biopsy where there is proteinuria, impaired/declining eGFR or uncertainty; score MEST-C for prognosis
- Maximal supportive (kidney-protective) care first-line: BP control to <=120/70 mmHg where tolerated, maximally titrated ACEi or ARB to reduce proteinuria, lifestyle (salt restriction, smoking cessation, weight)
- Add an SGLT2 inhibitor for persistent proteinuria/CKD (as per CKD evidence) — now standard supportive therapy
- Reassess proteinuria after optimised supportive therapy; identify patients at high risk of progression (persistent proteinuria >0.75-1 g/day despite optimisation, declining eGFR, adverse MEST-C)
- For high-risk progressive disease, discuss disease-targeted therapy: a 9-month course of targeted-release budesonide (Nefecon), or a reduced-dose systemic glucocorticoid regimen with infection (PCP) prophylaxis where Nefecon unavailable (KDIGO 2025)
- Consider endothelin receptor antagonist (sparsentan) as an alternative to RAS blockade to reduce proteinuria in appropriate patients (avoid in pregnancy — teratogenic) [verify local availability]
- Treat crescentic/RPGN variant aggressively (steroids +/- cyclophosphamide) as for RPGN; manage AKI supportively
- Long-term nephrology follow-up with periodic proteinuria/eGFR monitoring and CV risk reduction
Drugs & doses
Disposition
Complications & pitfalls
- Progressive CKD and kidney failure (up to ~20-40% over 10-20 years in biopsied cohorts)
- Hypertension
- Rapidly progressive (crescentic) glomerulonephritis
- AKI (synpharyngitic haematuria-associated or crescentic)
- Recurrence in renal transplant
Exam pearls
- Synpharyngitic haematuria (haematuria at the SAME time as a sore throat/mucosal infection) points to IgAN; a 1-3 week latent period after pharyngitis/skin infection with LOW C3 points to post-streptococcal GN.
- KDIGO 2025 IgAN guideline: optimise supportive therapy (RASi or endothelin receptor antagonist +/- SGLT2i, BP <=120/70) FIRST; reserve a 9-month Nefecon course or reduced-dose steroids for those still at risk of progression.
- C3 is characteristically NORMAL in IgA nephropathy — a persistently low C3 should prompt reconsideration (post-strep, lupus, MPGN).
- MEST-C Oxford histological score guides prognosis and the immunosuppression decision — the biopsy is worth it when there is proteinuria or impairment.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.